Shire Pharmaceuticals Group Plc

Shire Added to Global 100 Sustainability Index

Lexington, Massachusetts And Zug, Switzerland (ots/PRNewswire) - Shire plc announces that it has for the first time placed in the Global 100 Sustainability Index. Shire was ranked 62nd in the index, which is being revealed during the World Economic Forum in Davos this week.

The Global 100 Index is a global ranking by Canada-based media and investment advisory company, Corporate Knights, of the top sustainability performers and has come to be recognised as the gold standard in corporate sustainability analysis. The Global 100 Index is determined from public data using twelve quantitative sustainability indicators which include leadership diversity, employee compensation, tax paid, innovation capacity, and energy and water use, among others.

Shire's Chief Executive Officer, Flemming Ornskov, MD, MPH, commented:

"We appreciate the recognition for Shire's approach to being a sustainable, responsible business. Our patients rely on us and our products to live better lives, and having an ethical and responsible approach to our daily activities, policies and programs is fundamental for our future, our patients' future, and the wider global community."

Read more about Shire's approach to Responsibility at http://www.shire.com/cr

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal, and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.

http://www.shire.com

Contact:

For further information please contact:
Media
Brooke Clarke
brclarke@shire.com
+44-1256-894-829

Robert Stanislaro
robert.stanislaro@fticonsulting.com
+1-646-421-9067

Irma Gomez-Dib
irma.gomez-dib@fticonsulting.com
+1-415-706-9155



Weitere Meldungen: Shire Pharmaceuticals Group Plc

Das könnte Sie auch interessieren: